BrainCool AB (publ) receives new patent approval in USA

BrainCool has received a “Notice of Allowance” from the US Patent and Trademark Office (application 5/171,858 US) for the product RhinoChill™ System.

CEO Martin Waleij comments;

-        We welcome the patent approval, which marks an important success. We believe that RhinoChill™ has significant potential in the US market. In 2019, BrainCool is focusing on the launch of the product in the German market, where several hospitals have decided to introduce the product for early cooling treatment in ambulance. At this year's American Heart meeting (Philadelphia, November 16-18), new studies with the product will be presented.

BrainCool's patent structure for RhinoChill™ consists of 4 patent families, where the product RhinoChill™ now has 14 patents granted in the United States. New patents and intellectual property rights for the product, especially against migraine and military applications, are also being developed within an EU-funded project (called CoolHead) in collaboration with Lund’s University.

The patent families refer to devices for cooling the nasal cavity, cooling of localized areas of the body for cerebral blood flow increase, methods and devices for non-invasive cerebral and systemic cooling through the nasal cavity, as well as methods and devices for non-invasive cerebral and systemic cooling with stroke or cardiogenic shock caused by decreased cerebral perfusion or in the treatment of migraine.

In 2019, the focus is on launching the product in Germany, which is the largest and most important market in Europe.

For more information

Martin Waleij - CEO                                                               
+46 - 733 -93 70 76                                                                                          
E-mail: martin.waleij@braincool.se                       

About BrainCool AB (publ)

BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Pain Management. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Spotlight Stock Market.